• Hutchison MediPharma Ltd., of London, began a Phase I trial of theliatinib (HMPL-309) in advanced solid tumors. The objectives of the study are safety and tolerability, as well as determining the maximum tolerated dose. Efficacy against non-small-cell lung cancer and pharmacokinetics also will be evaluated. Theliatinib is an inhibitor of epidermal growth factor receptor (EGFR) that has shown strong antitumor activity against EGFR wild-type tumors in preclinical studies.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5476
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST